The relationship between ezrin and podoplanin expressions in keratocystic odontogenic tumors

BMC Oral Health

Fernando Augusto Soares¹  José Roberto Pereira Lauris²  Suely Nonogaki³  Kellen Cristine Tjioe⁴  Agnes Assao⁴  Laís Priscila de Santis⁴  Denise Tostes Oliveira⁴ 

[1] Department of Pathology, A.C. Camargo Cancer Hospital, São Paulo, Brazil;Department of Community Dentistry, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil;Adolfo Lutz Institute, Pathology Division, São Paulo, Brazil;Department of Stomatology, Area of Pathology, Bauru School of Dentistry, University of São Paulo, Alameda Octávio Pinheiro Brisolla, 9-75, 17012-901 Bauru, São Paulo, Brazil

关键词: Podoplanin;    Ezrin;    Keratocystic odontogenic tumor;   

Others  :  1090889
DOI  :  10.1186/1472-6831-14-150

 received in 2014-08-13, accepted in 2014-11-18,  发布年份 2014

【 摘 要 】

Background

The aims of this study were to investigate the immunolocalization of ezrin and its relationship with the podoplanin expression in keratocystic odontogenic tumors.

Material and Methods

The immunohistochemical expressions of ezrin and podoplanin by odontogenic epithelium were evaluated in keratocystic odontogenic tumors using monoclonal antibodies.

Results

Our results showed strong cytoplasmic ezrin and membranous podoplanin expressions in basal epithelial layer of all keratocystic odontogenic tumors. The cytoplasmic and membranous ezrin expressions were also detected in suprabasal epithelial layers of tumors. Statistically significant difference between cellular immunolocalization of ezrin and podoplanin odontogenic epithelium were found by Wilcoxon’s test (p < 0.05). No correlation between both proteins in keratocystic odontogenic tumors was detected by Spearman test.

Conclusions

These results suggest that ezrin and podoplanin may contribute to the expansive growth and local invasiveness of keratocystic odontogenic tumors. Additionally, as both proteins were overexpressed by odontogenic epithelium, their possible roles need to be further explored in benign odontogenic tumors.

【 授权许可】

   
2014 Oliveira et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sawa Y, Iwasawa K, Ishikawa H: Expression of podoplanin in the mouse tooth germ and apical bud cells. Acta Histochem Cytochem 2008, 41:121-126.
• [2]Imaizumi Y, Amano I, Tsuruga E, Kojima H, Sawa Y: Immunohistochemical examination for the distribution of podoplanin-expressing cells in developing mouse molar tooth germs. Acta Histochem Cytochem 2010, 43:115-121.
• [3]González-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, Yoshida N, Kikuchi K, Ide F, Sakashita H, Kusama K: Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med 2010, 39:103-109.
• [4]Okamoto E, Kikuchi K, Miyazaki Y, Gonzalez-Alva P, Oku Y, Tanaka A, Yoshida N, Fujinami M, Ide F, Sakashita H, Kusama K: Significance of podoplanin expression in keratocystic odontogenic tumor. J Oral Pathol Med 2010, 39:110-114.
• [5]Zustin J, Scheuer HA, Friedrich RE: Podoplanin expression in human tooth germ tissues and cystic odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 2010, 39:115-120.
• [6]Gonzalez-Alva P, Inoue H, Miyazaki Y, Tsuchiya H, Noguchi Y, Kikuchi K, Ide F, Ishihara S, Katayama T, Sakashita H, Kusama K: Podoplanin expression in odontomas: clinicopathological study and immunohistochemical analysis of 86 cases. J Oral Sci 2011, 53:67-75.
• [7]Tjioe KC, Oliveira DT, Soares CT, Lauris JR, Damante JH: Is podoplanin expression associated with the proliferative activity of ameloblastomas? Oral Dis 2012, 18:673-679.
• [8]Friedrich RE, Scheuer HA, Zustin J: Expression of podoplanin in nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumours. Anticancer Res 2012, 32:2125-2127.
• [9]Caetano Ados S, Tjioe KC, Faustino SE, Hanemann JA, Belone Ade F, Soares CT, Oliveira DT: Immunolocalization of podoplanin in benign odontogenic tumours with and without ectomesenchyme. Arch Oral Biol 2013, 58:408-415.
• [10]Zhang X, Wang J, Ding X, Xing S, Zhang W, Wang L, Wu H, Wang L: Altered expression of podoplanin in keratocystic odontogenic tumours following decompression. Oncol Lett 2014, 7:627-630.
• [11]Martin-Villar E, Fernandez-Munoz B, Parsons M, Yurrita MM, Megias D, Perez-Gomez E, Jones GE, Quintanilla M: Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell 2010, 21:4387-4399.
• [12]Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9:261-272.
• [13]Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006, 119:4541-4553.
• [14]Arpin M, Chirivino D, Naba A, Zwaenepoel I: Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr 2011, 5:199-206.
• [15]Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004, 10:175-181.
• [16]Barnes LEJW, Reichart P, Sidransky D: Odontogenic Tumors. In World Health Organization Classification of Tumours - Pathology and genetics - Head and neck Tumours. Lyon, France: IARC Press I; 2005:284-327.
• [17]Tsuneki M, Maruyama S, Yamazaki M, Cheng J, Saku T: Podoplanin expression profiles characteristic of odontogenic tumor-specific tissue architectures. Pathol Res Pract 2012, 208:140-146.
• [18]Madan R, Brandwein-Gensler M, Schlecht NF, Elias K, Gorbovitsky E, Belbin TJ, Mahmood R, Breining D, Qian H, Childs G, Locker J, Smith R, Haigentz M Jr, Gunn-Moore F, Prystowsky MB: Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck 2006, 28:1018-1027.
• [19]Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M, Allal AS: Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy. J Clin Pathol 2007, 60:185-189.
• [20]Saito S, Yamamoto H, Mukaisho K, Sato S, Higo T, Hattori T, Yamamoto G, Sugihara H: Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS ONE 2013, 8:e54881.
• [21]Schlecht NF, Brandwein-Gensler M, Smith RV, Kawachi N, Broughel D, Lin J, Keller CE, Reynolds PA, Gunn-Moore FJ, Harris T, Childs G, Belbin TJ, Prystowsky MB: Cytoplasmic ezrin and moesin correlate with poor survival in head and neck squamous cell carcinoma. Head Neck Pathol 2012, 6:232-243.
• [22]dos Santos AA, Oliveira DT, Pereira MC, Faustino SE, Nonogaki S, Carvalho AL, Kowalski LP: Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance. Anticancer Res 2013, 33:3969-3976.